Guilford Gliadel Survival Data Could Address FDA “Non-Approvable” Letter
This article was originally published in The Gray Sheet
Executive Summary
Guilford Pharmaceuticals may submit Gliadel Wafer patient survival data to help address concerns outlined in FDA's "non-approvable" letter for newly diagnosed malignant glioma